



1-30-04

1641

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/831,123
Applicant : Kinkade et al.
Filed : August 13, 2001
TC/A.U. : 1641
Examiner : Cook, Lisa V.
For : BIOMARKERS FOR OXIDATIVE STRESS
Docket No. : 68-97
Customer No. : 23713

Confirmation No. 8722

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for Express Mail in an envelope addressed to:

Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450

January 28, 2004
Date

Cathy Nelson
Cathy Nelson

EV 412171604 US
Express Mail Tracking Number

Commissioner for Patents
OFFICIAL DRAFTSPERSON
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER TO OFFICIAL DRAFTSPERSON

Sir,

Included herewith are Formal Drawings for the above-referenced case, which include Figures 1 through 16 on 17 pages.

It is believed no fee is due with this submission however if this is incorrect, please deduct the appropriate fee and any extensions of time necessary from deposit account 07-1969.

RECEIVED

Respectfully submitted,

FEB 05 2004

Susan K. Doughty CENTER 1600/2900
Susan K. Doughty
Reg. No. 43,595

GREENLEE, WINNER AND SULLIVAN, P.C.
5370 Manhattan Circle, Suite 201
Boulder, CO 80303
Telephone: (303) 499-8080
Facsimile: (303) 499-8089
E-mail: winner@greenwin.com
Attorney docket No. 68-97
can: January 28, 2004




Biomarkers for Oxidative Stress

Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01

FIG. 1



RECEIVED


FEB 05 2004

TECH CENTER 1600/2000

Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01



RECEIVED

FEB 05 2004

TAKEN







Figure 4



RECEIVED

FEB 05 2004

TABLE OF CONTENTS



Biomarkers for Oxidative Stress

Inventors: Kinkade et al.
Atty Docket: 68-97
USSN: 09/831,123 Filed: 8/13/01

Coomasie





FIG. 5A



FIG. 5B

RECEIVED
FEB 05 2004
TECH CENTER 1640
1 2 3 4 5 6 7 8 9 10



▨ MBP vs anti-MBP
▨ MBP vs anti-OVA

FIG. 6

RECEIVED

FEB 05 2004

TECH CENTER 1600
1600



FIG. 7A





FIG. 7B






Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01

FIG. 8

- ▨ HOOH oxidized HSA containing 27.9 pmol cysteic acid/μg protein
- ▨ HOOH oxidized HSA containing 11.7 pmol cysteic acid/μg protein
- ▨ HOOH oxidized HSA containing 4.0 pmol cysteic acid/μg protein
- ▨ Unoxidized HSA


Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01



FIG. 9A

10
RECEIVED

FEB 05 2004

C 160713000

FIG. 9B








Figure 10

Reactivity of mAB against PAoxBSA and unoxidized BSA

Wells coated with either 1 μ g of PAoxBSA or 1 μ g of unoxidized BSA.

RECEIVED
FEB 05 2004
SEARCH CENTER 1600/200

Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01



Figure 11
Plate A - 96-well template

	1	2	3	4	5	6	7	8	9	10	11	12
A	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g PAox	OVA + GSA	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
B	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g PA	ox OVA	K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
C	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g C	M-OVA	K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
D	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g OVA	OVA	K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
E	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g OVA	-oxCAP 37	K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
F	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g OVA-u	noxCA P 37	K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
G	1 μ g PA	ox OV A	1 μ g OVA-	oxCAP 37	K2.A12	K2.A12	K2.A12	K2.A12	K2.A12	K2.A12	K2.A12	K2.A12
H	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g PAox	OVA + CA	K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6


RECEIVED

FEB 05 2004

U.S. PATENT AND TRADEMARK OFFICE



Figure 12A - ELISA on PAoxOVA of Normal Kids
(ages 12-16) #1-54 : Plasma at 1:200









FIG. 13 - Patient Sera (1/1000)



Patient Number

RECEIVED


FEB 05 2004

WCE: 7/29/16 10:12



FIG. 14

ELISA of Patient Sera (1:200) on PAoxOVA in the absence (col 1) and presence of oxOVA (col 2). Percent Inhibition uncorrected for the blank.




Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01



FIG. 15 - Bailey Renal Patient Plasma 1:200



RECEIVED

FEB 05 2004

U.S. PATENT AND TRADEMARK OFFICE

Inventors: Kinkade et al.

Atty Docket: 68-97

USSN: 09/831,123 Filed: 8/13/01




Figure 16A




Figure 16B